Key clinical point: Combination sacubitril/valsartan showed a beneficial effect in heart failure with preserved ejection fraction and in women more so than men.
Major finding: The combined treatment group had 12% overall lower all-cause mortality.
Study details: Pooled analyses of 13,195 patients from the PARAGON-HF and PARADIGM-HF trials.
Disclosures: Novartis sponsored the studies. Dr. McMurray has no disclosures. Dr. Solomon disclosed financial relationships with trial sponsor Novartis along with numerous pharmaceutical companies and the National Heart, Lung, and Blood Institute.
McMurray JJ and Solomon SD. AHA 2019, Late Breaking Science Session 5.